Adrian Rawcliffe
2021
In 2021, Adrian Rawcliffe earned a total compensation of $4.2M as Chief Executive Officer at Adaptimmune Therapeutics, a 56% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $351,719 |
|---|---|
| Option Awards | $3,207,291 |
| Salary | $617,050 |
| Other | $38,941 |
| Total | $4,215,001 |
Rawcliffe received $3.2M in option awards, accounting for 76% of the total pay in 2021.
Rawcliffe also received $351.7K in non-equity incentive plan, $617.1K in salary and $38.9K in other compensation.
Rankings
In 2021, Adrian Rawcliffe's compensation ranked 3,169th out of 12,415 executives tracked by ExecPay. In other words, Rawcliffe earned more than 74.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,169 out of 12,415 | 75th |
Division Manufacturing | 1,279 out of 5,505 | 77th |
Major group Chemicals And Allied Products | 523 out of 2,375 | 78th |
Industry group Drugs | 464 out of 2,096 | 78th |
Industry Biological Products, Except Diagnostic Substances | 126 out of 449 | 72nd |
Pay ratio
| Adrian Rawcliffe's Pay | $4,215,001 |
|---|---|
| Median Employee's Pay | $126,493 |
| Pay Ratio | 33to 1 |
In 2021, the annual total compensation of Adrian Rawcliffe was $4,215,001.
The annual total compensation of the median employee at Adaptimmune Therapeutics was $126,493.
The ratio of Adrian Rawcliffe's pay to the pay of median employee was therefore 33 to one.
Source: SEC filing on April 21, 2022.
Rawcliffe's colleagues
We found four more compensation records of executives who worked with Adrian Rawcliffe at Adaptimmune Therapeutics in 2021.